Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Bill Anderson's replacement as chief executive of Roche Pharmaceuticals has been announced, with head of global product strategy Teresa Graham stepping up into the role. Anderson's departure was ...

Originally, blood-check meters were large and bulky and used only in hospitals, but the latest version, CoaguChek, is a handheld device which can determine within two minutes whether a patient is ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...